As healthcare continues its transition towards precision medicine, physicians are eager to maximize both the quantity and quality of data obtained from their patients’ tissue samples. In the current “one drug, one test” paradigm, physicians struggle to balance the number of tests required to make a treatment decision with the limited amount of tissue that is available. Further complicating treatment decisions is the use of imperfect biomarkers associated with targeted therapies, as the patients who are identified to be ideal candidates for a targeted therapy respond only some of the time while patients who are not expected to respond do. This dilemma is of great concern for those who are responsible for paying for these expensive therapies - payers and patients – who would like to avoid unnecessary expenses for drugs that may not work and possibly cause debilitating side effects. Of course, of even greater concern is helping the patient identify the best therapeutic option that allows them the best opportunity to treat their disease and maximize their quality and quantity of life.Read More
Topics: image analysis, precision medicine, personalized medicine, immuno-oncology, biomarker, tissue biomarkers, diagnostics, tissue diagnostics, diagnostic test, biomarker signature, companion diagnostics
With so much going on the field of immunotherapy and immuno-oncology, Definiens would like to provide you with a quick resource of some of the latest news updates you may have missed. Enjoy the reading and we hope you find it informative!
Gene Alterations in Melanoma May Predict Immunotherapy Outcome
Summary of a retrospective study on how NRAS gene mutations affect treatment response and outcomes of melanoma patients.
Activated Immune Cells Correlate With Promising Disease Outcome
Findings of a German research team who discovered an important association between increased levels of TNF alpha in colorectal tumor tissue and an increased number of activated cytotoxic T cells.
Arming the Immune System Against Cancer
James P. Allison on the history of immunotherapy and his research work at the immunology department at the University of Texas M.D. Anderson Cancer Center, Houston.
What if there was a long-term cure for cancer? What if one could teach the body how to recognize and fight cancer cells not only transiently, but forever? What if tumor recurrence and metastasis were a story of the past?
The Evolution of Immunotherapy
With immunotherapy and immuno-oncology gaining momentum, these ideas could become a reality. In the last several years, not only have checkpoint inhibitors been the primary focus of many studies, but the approval of Yervoy® (ipilimumab) served as a key breakthrough for those in the field of cancer immunotherapy. What makes immunotherapy unique compared to other approaches is the potential for a long-lasting cure, with studies showing subsets of patients who have previously failed with other treatments experiencing a complete, long-term remission after immunotherapy treatment.
Clinical trial results like these have not gone unnoticed. The recent surge in acquisitions, partnership agreements, and licensing deals clearly highlight just how many resources the biopharmaceutical industry is focusing in both the areas of immunotherapy and immuno-oncology.